SANGAMO THERAPEUTICS, INC Uncategorized Contracts & Agreements

30 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Placement Agent Agreement, dated March 21, 2024 by and among Sangamo Therapeutics, Inc. and Barclays Capital Inc. and Cantor Fitzgerald & Co
SANGAMO THERAPEUTICS, INC
Biotechnology
NY
2024
Letter Agreement between the Company and David Mark McClung dated November 1, 2021
SANGAMO THERAPEUTICS, INC
Biotechnology
CA
2022
Letter Agreement between the Company and
SANGAMO THERAPEUTICS, INC
Biotechnology
CA
2021
Letter Agreement between the Company and
SANGAMO THERAPEUTICS, INC
Biotechnology
CA
2021
Letter Agreement between the Company and
SANGAMO THERAPEUTICS, INC
Biotechnology
CA
2021
Letter Agreement between the Company and
SANGAMO THERAPEUTICS, INC
Biotechnology
2021
Description of
SANGAMO THERAPEUTICS, INC
Biotechnology
2021
Letter Agreement dated as of January 22, 2021 between Sangamo Therapeutics, Inc. and Sung Lee
SANGAMO THERAPEUTICS, INC
Biotechnology
CA
2021
Letter Agreement
SANGAMO THERAPEUTICS, INC
Biotechnology
2020
Open Market Sale Agreement, dated August 5, 2020, between Sangamo Therapeutics, Inc. and Jefferies LLC
SANGAMO THERAPEUTICS, INC
Biotechnology
NY
2020
Form of Indemnity Agreement
SANGAMO THERAPEUTICS, INC
Biotechnology
DE
2020
Description of Securities of the Company
SANGAMO THERAPEUTICS, INC
Biotechnology
2020
Amendment No. 1 to the Tender Offer Agreement dated October 1, 2018, between the Company and TxCell
SANGAMO THERAPEUTICS, INC
Biotechnology
2018
Tender Offer Agreement dated July 20, 2018, between the Company and TxCell
SANGAMO THERAPEUTICS, INC
Biotechnology
2018
Offer Letter between the Company and Curt A. Herberts, dated August 16, 2010
SANGAMO THERAPEUTICS, INC
Biotechnology
2018
Exhibit A
SANGAMO THERAPEUTICS, INC
Biotechnology
2016
NINTH AMENDMENT
SANGAMO THERAPEUTICS, INC
Biotechnology
2014
*** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION
SANGAMO THERAPEUTICS, INC
Biotechnology
2011
*** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION
SANGAMO THERAPEUTICS, INC
Biotechnology
2011
*** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 2.
SANGAMO THERAPEUTICS, INC
Biotechnology
2008
*** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION
SANGAMO THERAPEUTICS, INC
Biotechnology
2008
SANGAMO BIOSCIENCES, INC.
SANGAMO THERAPEUTICS, INC
Biotechnology
CA
2007
our strategy
SANGAMO THERAPEUTICS, INC
Biotechnology
DE
2007
Current assets
SANGAMO THERAPEUTICS, INC
Biotechnology
CA
2007
SANGAMO BIOSCIENCES, INC. 3,000,000 SHARES
SANGAMO THERAPEUTICS, INC
Biotechnology
NY
2007
our strategy
SANGAMO THERAPEUTICS, INC
Biotechnology
NY
2007
our strategy
SANGAMO THERAPEUTICS, INC
Biotechnology
DE
2006
/s/ Dr. Casey Case Dr. Casey Case November 18, 2005 Date
SANGAMO THERAPEUTICS, INC
Biotechnology
2005
our strategy
SANGAMO THERAPEUTICS, INC
Biotechnology
2005
THIRDAMENDMENT TO LICENSEAGREEMENT
SANGAMO THERAPEUTICS, INC
Biotechnology
2004